Brief: NRX Pharmaceuticals Announces Strategic Change In Development Of Nrx-100 (IV Ketamine)

NRX Pharmaceuticals

12/10/2023 11:56

Oct 12 (Reuters) - NRX Pharmaceuticals Inc  NRXP.O :
    * NRX PHARMACEUTICALS ANNOUNCES STRATEGIC CHANGE IN
DEVELOPMENT OF
NRX-100 (IV KETAMINE) AT DAWSON JAMES SMALL CAP INVESTOR
CONFERENCE
    * NRX: NEWLY AVAILABLE DATA HIGHLIGHT NEED FOR A LABELED
FORM OF
IV KETAMINE THAT CAN QUALIFY FOR INSURANCE REIMBURSEMENT
    * NRX PHARMACEUTICALS INC - NEED FOR INTRAVENOUS KETAMINE
HEIGHTENED BY RECENT FAILURE OF INTRANASAL KETAMINE TO TREAT
SUICIDALITY

Source text for Eikon:  ID:nPn5ZlBJha 
Further company coverage:  NRXP.O 

 ((Reuters.Briefs@thomsonreuters.com;))